Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.

  title={Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.},
  author={A. Rupin and P. Mennecier and C. Lila and G. de Nanteuil and T. Verbeuren},
  journal={Thrombosis and haemostasis},
  volume={78 4},
  • A. Rupin, P. Mennecier, +2 authors T. Verbeuren
  • Published 1997
  • Chemistry, Medicine
  • Thrombosis and haemostasis
  • Using enzymatic microassays, the potency of a series of new boroarginine tripeptides was determined versus thrombin and a panel of serine-proteases implicated in the coagulation and fibrinolysis pathways. The inhibition of the serine-protease complement factor I was also studied. Factor I regulates the alternate pathway of the complement and its inhibition appears to be responsible for the toxic effects of the orally available thrombin inhibitor Ac-D-Phe-Pro-boroArg (DuP-714). The structure of… CONTINUE READING
    14 Citations
    S35972, a direct‐acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy
    • 5
    Kinetic Investigation and Anticoagulant Activity of Amide Analogues of Isoform 2 and 3 of Antistasin
    Direct thrombin inhibitors – a survey of recent developments
    • 82
    Advances in the development of thrombin inhibitors
    • 60
    Complement factor I in health and disease.
    • 108
    • PDF